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IFN-γ-producing T helper 1 (Th1) cell responses mediate protection against infections
but uncontrolled Th1 activity also contributes to a broad range of autoimmune diseases.
Autocrine complement activation has recently emerged as key in the induction and con-
traction of human Th1 immunity: activation of the complement regulator CD46 and the
C3aR expressed by CD4+ T cells via autocrine generated ligands C3b and C3a, respec-
tively, are critical to IFN-γ production. Further, CD46-mediated signals also induce co-
expression of immunosuppressive IL-10 in Th1 cells and transition into a (self)-regulating
and contracting phase. In consequence, C3 or CD46-deficient patients suffer from recur-
rent infections while dysregulation of CD46 signaling contributes to Th1 hyperactivity in
rheumatoid arthritis and multiple sclerosis. Here, we report a defect in CD46-regulated
Th1 contraction in patients with systemic lupus erythematosus (SLE). We observed that
MMP-9-mediated increased shedding of soluble CD46 by Th1 cells was associated with
this defect and that inhibition of MMP-9 activity normalized release of soluble CD46 and
restored Th1 contraction in patients’ T cells. These data may deliver the first mecha-
nistic explanation for the increased serum CD46 levels observed in SLE patients and
indicate that targeting CD46-cleaving proteases could be a novel avenue to modulate Th1
responses.
Keywords: Autoimmunity  CD46  Complement  Innate immunity  Membrane cofactor
protein  T cell  Th1
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune
disease of uncertain etiology [1]. One hallmark of SLE is dys-
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regulated cytokine production, which contributes to immune dys-
function and tissue inflammation [2]. Type I and II interferons
(IFN) [3] have been implicated in SLE induction and progression.
Although much emphasis has been placed on type I IFNs [4],
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numerous reports indicate that increased levels of the single type
II interferon, IFN-gamma (IFN-γ), is required in both spontaneous
and induced animal models of SLE [5, 6].
CD4+ T helper type 1 (Th1) lymphocytes are a major source of
IFN-γ [7, 8]. In humans, additional signals (aside from CD28),
mediated by the complement regulator CD46 have recently
emerged as crucial to Th1 induction [9–11]. CD46 was initially
discovered as a complement regulatory protein functioning: a
cell-surface cofactor mediating cleavage of C3b and C4b [12].
Interestingly, engagement of CD46 on TCR-stimulated CD4+
T cells seems largely independent of serum-derived C3b, rather
T cell CD46 stimulation is mediated by T-cell-derived C3b (gen-
erated intra- and extra-cellularly via cathepsin L-induced cleav-
age of C3). Such autocrine C3b-driven CD46 engagement deliv-
ers signals to the T cells that induce the controlled regulation of
IL-2 receptor (IL-2R) expression [10] and reprogramming specifi-
cally needed for IFN-γ secretion [11]. Furthermore, while lack of
CD46 co-stimulation during T-cell activation (in patients with C3
or CD46 deficiency) leads to severely reduced Th1 responses and
recurrent infections [10, 11, 13], pathologically increased intra-
cellular C3 activation and autocrine CD46 simulation is connected
with the hyperactive Th1 responses present in rheumatoid arthritis
(RA) [14].
CD46-mediated signals are not only required for successful
Th1 induction (IFN-γ+ cells), they also contribute to Th1 contrac-
tion. CD46 engagement, together with currently undefined signals
mediated by the IL-2R, leads to IL-10 co-expression in Th1 cells
and the induction of a (self)-regulatory (IFN-γ+ IL-10+ T cell)
and finally contracting phase with IL-10+ Th1 cells [9, 15]. Dys-
regulated CD46 signals during the contracting phase prevent nor-
mal IFN-γ shut-down and the switch into normal Th1 contraction
and contribute to disease pathology in RA and multiple sclerosis
(MS) [15, 16].
Thus, cell surface expression of CD46 is tightly regulated in
various cell types and it has long been known that the extra-
cellular portion of CD46 is rapidly down-regulated post CD46
activation [17]. CD46’s ‘disappearance’ is due to both the regu-
lated internalization of the molecule [17] and to CD46 shedding
via matrix metalloproteinases (MMPs) [18]. Although the func-
tional significance of CD46 shedding is not fully understood, we
recently demonstrated that CD46 expression on resting T cells
contributes to T-cell homeostasis as CD46 interacts directly with
Jagged1 and prevents a Notch1-Jagged1 interaction that would
normally promote T-cell activation [10]. TCR-induced C3b gener-
ation and autocrine CD46 engagement leads to shedding of CD46
(with the CD46-cleaving protease not yet defined), which then
allows a productive Notch1-Jagged1 interaction required for nor-
mal human Th1 induction [19]. Thus, CD46 surface expression
on non-stimulated T cells acts as a ‘stop signal’, but provides a
‘go signal’ when immune activation is apparent. Importantly, sol-
uble CD46 (sCD46) generated during normal T-cell activation can
also modulate Notch1-mediated signals on T cells and impacts sig-
nificantly on IFN-γ to IL-10 switching and Th1 contraction [10].
Intriguingly, increased levels of sCD46 have been reported in sera
of patients with RA, MS, and SLE [20, 21]. Together, these obser-
vations prompted us to investigate expression and processing of
CD46 as well as the CD46-driven Th1 induction and contraction
‘states’ of CD4+ T cells from patients with SLE in vitro.
Results
Th1 contraction is defective in CD4+ T cells from
patients with SLE
Initial signals through CD46 are required for Th1 induction
and IFN-γ secretion; while later, CD46 induces co-production of
immunosuppressive IL-10 and Th1 contraction [9, 15]. To assess if
perturbation in the complement-CD46-driven pathways contribute
to dysregulated Th1 responses observed in SLE, we activated this
pathway in purified CD4+ T cells from healthy controls (HCs) and
individuals with SLE (see Methods) and measured active IFN-γ
and IL-10 secretion. SLE CD4+ T cells showed a statistically sig-
nificant increase in IFN-γ-positive T cells when compared to HC
T cells following CD3 activation and, furthermore, failed to switch
efficiently from IFN-γ to IL-10 production following CD3+CD46
stimulation (Fig. 1A and B). In addition, SLE T cells secreted sig-
nificantly higher (up to 300%) amounts of IFN-γ while IL-10 levels
were substantially reduced (up to 300%) after CD3+CD46 stim-
ulation (Fig. 1C). This shifted the IFN-γ:IL-10 ratio significantly
toward IFN-γ in SLE compared to controls. Importantly, CD46-
mediated signals were specifically required for normal Th1, but
not Th2 responses, because the IL-4 and IL-5 levels were unal-
tered in SLE T cells after CD3+CD46 activation (Fig. 1D) or
after CD3 and CD3+CD28 stimulation (not shown). Recent work
demonstrates that complement C3 can be cleaved intracellularly
by cathepsin L into C3a/C3b by human CD4+ T cells [14]. TCR
activation translocates these stored activation products rapidly to
the cell surface were C3b engages CD46 to induce IFN-γ. Inter-
estingly, CD3+CD46-activated T cells from SLE patients secrete
significantly higher levels of C3b compared to HCs (Fig. 1E)
T cells, indicating the autocrine C3-CD46 axis is perturbed in
T cells from SLE patients.
Dysregulation of Th1 contraction (IL-10 switching)
persists over time in SLE patients
SLE commonly exhibits fluctuation in activity over time and we
therefore askedwhether the CD46-mediated switching of Th1 cells
into an IL-10-producing regulatory and contracting phase was per-
sistently defective in SLE. To this end, we first analyzed the number
of total IFN-γ (IFN-γ+IL-10− andIFN-γ+IL-10+) or IL-10-positive
(IFN-γ+IL-10+ and IFN-γ−IL-10+) T cells from HCs and individu-
als with SLE after CD3 and CD3+CD46 activation (Fig. 2A, time
‘0’). After 4 months, the same HCs and SLE patients provided a sec-
ond blood sample and the assays were repeated (Fig. 2A, time ‘4
months’). These experiments demonstrated that in the majority of
those with SLE, the reduction in effective IL-10 switching and Th1
contraction was sustained over time and remained part of their
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 1. CD46-regulated Th1 contraction (IFN-γ to IL-10
switching) is defective in Th1 cells from patients with SLE.
(A) Active cytokine secretion at 36 h by purified CD4+ T cells
from healthy controls (HC, upper row) or SLE patients (lower
row) not activated or activated with mAbs to CD3 alone or
to CD3 and CD46. Numbers in plots indicate percent IFN-γ+
IL-10− cells (top left), IFN-γ+IL-10+ cells (top right) or IFN-γ−
IL-10+ cells (bottom right). One representative FACS analysis
of 38 independent healthy controls is shown. (B) Summary of
altered cytokine secretion of CD3, and CD3+ CD46-activated
CD4+ T cells of patients with SLE. Experiments were per-
formed as under (A) with CD4+ T cells of HCs (n = 38) and
patients with SLE (n = 45) and cumulative data of 35 inde-
pendent experiments are shown. Data are plotted as per-
centages of either total numbers of IFN-γ-positive (IFN-γ+
IL-10− and IFN-γ+IL-10+) or IL-10-positive (IFN-γ+IL-10+ and
IFN-γ−IL-10+) cells. (C and D) IFN-γ, IL-10 (C), IL-4 and IL-5 (D)
accumulation in cell supernatants of CD3+CD46-activated T
cells from HCs and SLE patients 36 h post activation. Data
are shown as mean ± SD and are representative of 20 exper-
iments using 10 HCs and 10 SLE patients. (E) Increased pro-
duction of the CD46 ligand C3b by T cells from SLE patients.
Purified T cells were activated for 36 h as indicated and C3b
generation and secretionmeasured by ELISA. Data are shown
as mean ± SD derived from experiments using 8 HCs and
10 SLE patients. p values in (B-D) were calculated using the
Mann–Whitney U test. *p < 0.05; ***p < 0.0001.
pathological CD4+ T-cell activation profile. We next assessed for
a possible correlation between SLE disease activity, defined by the
disease activity index (SLEDAI). We observed a significant positive
correlation between increased numbers of IFN-γ-secreting (but not
for IL-10-secreting) T cells after CD3 activation and disease activity
(Fig. 2B). Somewhat surprisingly, the numbers of IL-10-secreting
cells (after CD3+CD46 activation) also correlated positively with
disease activity (Fig. 2B). Of note, the IL-10-secreting cells in this
analysis contained both IFN-γ+IL-10+ and IFN-γ−IL-10+ cell pop-
ulations and it was previously shown that the IFN-γ+IL-10+ T cell
population in RA patients contributed mostly to disease [9].
Th1 cells from SLE patients fail to supress T-cell
proliferation and to support B-cell maturation
The inhibitory effect of IL-10 co-produced by contracting Th1
cells plays a key role in normal Th1 self-regulation and regulation
of bystander T cells and therefore maintenance of peripheral
tolerance [22].Hence, normally, cell supernatants isolated from
CD3+CD46-activated T cells are suppressive toward bystander
T cells due to their high IL-10 content [9, 15]. To assess the
regulatory capacity of CD46-activated SLE T cells, freshly isolated
autologous CD4+ T cells were activated with antibodies to either
CD3 or CD3+CD28 in the presence of supernatants derived
from CD3+CD46-activated T cells from HCs or SLE patients
and cell proliferation measured 6 days post-activation. The
supernatants derived from control T cells showed the expected
suppressive capacity and significantly inhibited proliferation of
CD3+CD28-activated T cells. This suppression was mediated
by IL-10 as neutralization of IL-10 fully restored bystander
T-cell activation (Fig. 3A). In contrast, cell supernatants from
CD3+CD46-activated SLE T cells had no suppressive capacity
and allowed for bystander proliferation comparable to HC T cells
cultured in fresh media (Fig. 3A).
Normally, CD46-activated CD4+ T cells support B-cell
proliferation and Ig class switching in an IL-10- and CD40L-
dependent manner [23]. We therefore investigated the effect
of CD46-activated supernatants from HCs and SLE patients
on B-cell maturation and class switching. B cells cultured in
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. Dysregulation of Th1 contraction (IL-10 switching) persists
over time in SLE patients. (A) CD4+ T cells of healthy controls (HCs, n= 6)
and SLE patients (n = 7) were activated for 36 h as indicated, analyzed
by flow cytometry, and plotted as percentages of either total numbers
of IFN-γ-positive (IFN-γ+IL-10− and IFN-γ+IL-10+) or IL-10-positive (IFN-
γ+IL-10+ and IFN-γ−IL-10+) cells. T cells were isolated again from the
same HCs and SLE patients 4 months later and analyzed in the same
fashion. (B) The relationship between disease activity index (SLEDAI)
and total numbers of CD46-induced IL-10-positive T cells is shown,
with each plot displaying the total numbers of IFN-γ-positive (IFN-γ+IL-
10− and IFN-γ+IL-10+) or IL-10-positive (IFN-γ+IL-10+ and IFN-γ−IL-10+)
cells. p and r values in (B) were calculated using the Pearson correlation
coefficient.
supernatants derived from CD3+CD46-activated HC T cells
showed significantly higher proliferation compared to B cells
cultured in supernatants of SLE T cells or fresh media (Fig. 3B).
The enhanced proliferation induced by HC T cell supernatants
was IL-10-dependent as the addition of a neutralizing antibody to
IL-10 abolished the increase proliferation (Fig. 3B). Supplemen-
tation of patients’ samples with rhIL-10 restored the support of B
cell proliferation given normally by T cell supernatants (Fig. 3B).
Similarly, supernatants from CD3+CD46-activated HC T cells also
supported plasmablast (CD19low/−/CD138+ cells) differentiation
in an IL-10-dependent manner as well as induction of IgM to
IgG class switching (Fig. 3C and D). In contrast, supernatants
from SLE T cells failed to support plasmablast differentiation or
immunoglobulin class switching [23].
Increased shedding of sCD46 by SLE T cells correlates
with lack of Th1 contraction
We next investigated the underlying cause of reduced IL-10 pro-
duction by SLE CD4+ T cells. To start, the levels of cell-surface
CD46 were measured together with CD46 transcript isoform
expression [24] in resting and activated T cells. Resting and
CD3-activated T cells isolated from HC and SLE patients showed
comparable levels of CD46 expression following CD3-activation
(Fig. 4A) and also no differences in the CD46 isoform (BC1, C1,
BC2, and C2) expression pattern (Fig. 4B). Further, CD46 sur-
face levels were reduced to the expected and equal amounts upon
CD3+CD46 stimulation on HC and SLE T cells (Fig. 4A). Thus, ini-
tial CD46 expression levels, and their isoform expression pattern
and the ability to induce CD46 shedding on resting and CD3-
activated T cells were comparable between HC and SLE patients.
Because increased levels of soluble CD46 (sCD46) have been
observed in SLE sera21 and we have demonstrated that sCD46
abrogates the CD46-mediated co-induction of IL-10 in Th1 by
interfering with normal Notch signaling [10], we next assessed
whether CD46 shedding may be altered in SLE T cells. Indeed,
while supernatants from CD3 and CD3+CD46-activated (after
36 h) HC T cells contained 2 and 8 ng/mL sCD46, respec-
tively, SLE T cells ‘produced’ 50 ng/mL sCD46 with CD3 acti-
vation and up to 300 ng/mL after CD3+CD46 stimulation
(Fig. 4C). The relationship between sCD46 and defective Th1 con-
traction was quantitative: increased sCD46 levels correlated pos-
itively with the increase of ‘faulty/non-suppressive’ IL-10-positive
cells in the SLE patients (Fig. 4D). Furthermore, sCD46 was
mainly detectable in samples from SLE patients with impaired
IL-10 switching, but not in those that had no switching defect
(Fig. 4E). Importantly, the addition of 50 ng/mL of rsCD46 to con-
trol T cells during CD3+CD46 activation was sufficient to inhibit
normal IFN-γ to IL-10 switching (Fig. 4F) and to tip the balance
significantly toward IFN-γ secretion as assessed by the IFN-γ:IL-10
producing T cells (Fig. 4G). Thus, T cells from patients with SLE
have increased CD46 shedding upon activation and such (local)
increased amounts of sCD46 prevent normal Th1 contraction, at
least in vitro.
MMP-9 mediates CD46 shedding by activated human
CD4+ T cells
Previous studies have shown that MMPs and their closely related
family of ADAMs can process the ectodomain of CD46 upon its
activation via crosslinking in different cell types [18, 25, 26].
We hypothesized that MMP-9 (gelatinase B) was a strong candi-
date in CD46 ectoderm shedding; first, because microarray anal-
ysis of CD3+CD46-activated CD4+ T cells revealed elevated lev-
els of MMP9 transcripts [11], and second, because anti-MMP-9
autoantibodies have been reported in SLE [27]. Indeed, blockade
of MMP-9 via a specific MMP-9 inhibitor during T cell activation
led to retention of CD46 on the cells surface in a dose-dependent
manner (Fig. 5A). The MMP-9 inhibition-mediated decrease in
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 3. Th1 cells from SLE fail to control bystander T cell proliferation and to support B cell maturation. (A)T cells from healthy con-
trols were activated with either anti-CD3 or anti-CD3 and anti-CD46 in fresh media or supernatants derived from CD3+CD46-activated
T cells of HCs (with and without addition of a function neutralizing Ab to IL-10) or in supernatants derived from CD3+CD46-activated
T cells from SLE patients. Cell/supernatant mixtures were activated for 6 days and proliferation analyzed. Data are shown as mean + SD and are
representative of five experiments (n= 5) using cells or supernatants from a different HC and SLE patient each time. (B and C). B cells fromHCswere
cultured in media or mixed with supernatants of CD4+ T cells derived from CD3 or CD3+CD46-activated T cells (36 h) from HCs or a patient with
SLE. Cell supernatants from HCs were also supplemented with anti-IL-10 Ab while cell supernatants from SLE patients were supplemented with
rhIL-10. Cell/supernatant mixtures were cultured for 10 days and (B) B-cell proliferation and (C) plasma blast cell differentiation (CS138highCD19low
B cells) measured. Data are shown as mean + SD or one representative FACS plot derived from five experiments (n = 5). (D) T cells from SLE
patients fail to support B-cell class switching. B cells from HCs were cultured for 10 days in supernatants from HC or SLE patient T cells activated
with either anti-CD3 or anti-CD3 and anti-CD46 and IgM and IgG secretion assessed by ELISA (n = 5). p values in (A) and (B) were calculated using
the Mann–Whitney U test. *p < 0.05.
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 4. Increased CD46 shedding by T cells from SLE patients contributes to faulty IL-10 switching. (A and B) T cells of healthy controls (HCs,
n = 10) and SLE patients (n = 15) were activated as indicated (36 h) and (A) CD46 surface expression analyzed by FACS and (B) CD46 isoform
expression assessed by RT-PCR in CD3-activated T cells. (C) Increased shedding of CD46 by CD3+CD46-activated Th1 cells from SLE patients. T
cells of HCs (n = 11) and SLE patients (n = 13) were stimulated for 36 h and sCD46 concentrations in cell supernatants analyzed by ELISA. (D)
Correlation analysis of sCD46 and IFNγ+IL-10+ Th1 cells from patients with SLE (n = 26) depicted as ratio of IL-10+ cells after CD3+CD46 activation.
Note, low values denote successful “switching” while high values correlate with “non-switching”. (E) Increased sCD46 concentrations in sera of SLE
patients with impaired switching (n = 16) compared to SLE patients with normal switching (n = 12) and HCs (n = 16) after CD3+CD46 activation.
(F) T cells of HCs were stimulated for 36 h as indicated either with or without addition of sCD46 (50 ng/mL) and. IFN-γ and IL-10-positive cells
enumerated. Shown is a representative FACS plot of five similarly performed experiments. (G) sCD46 tips the balance toward IFN-γ secretion. T
cells were activated as shown with or without addition of sCD46 and the ratio of IFN-γ to L-10 in supernatants assessed at 36 h. p and r values in
(D) were calculated using the Pearson correlation coefficient. p values in (C), (E) and (G) were calculated using the Mann–Whitney U test. *p < 0.05;
**p < 0.005, ***p < 0.0001.
CD46 shedding led to a modest reduction in IFN-γ secretion but
reduced IL-10 switching significantly (Fig. 5B). Of note, although
elevated levels of MMP-9 have been reported in sera of patients
with SLE [20] we did not observe a difference in MMP-9 released
by activated control or SLE T cells (Fig. 5C). Nonetheless, addition
of the specific MMP-9 inhibitor to activated HC T cells not only
reduced sCD46 generation but fully normalized sCD46 generation
by SLE patients’ T cells (Fig. 5D). Importantly, inhibition of MMP-9
activity also restored the impaired CD46-mediated IL-10 switching
and contraction of Th1 cells observed in SLE by increasing IL-10
production significantly and tipping the IFN-γ to IL-10 level ratio
back towards IL-10 (Fig. 5E). MMP-9 inhibition reduced IFN-γ pro-
duction modestly in HC T cells but significantly prevented IL-10
switching (Fig. 5E). The MMP-9 inhibitor has different effects with
regard to the IFN-γ to IL-10 production and/or ratio in HC and SLE
T cells because MMP-9 inhibition in HC T cells diminishes CD46
surface shedding and the release of the CD46 ‘brake’ on Notch
signaling (and hence reduces both initial IFN-γ induction and
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 5. MMP-9 inhibition restores Th1 contraction in SLE patients. (A and B) T cells were CD3+CD46 activated for 36 h in the presence of
increasing concentrations of an MMP-9-specific inhibitor and (A) CD46 expression assessed by FACS and (B) IL-10 and IFN-γ secretion measured by
CBA. Themean + SD of the results of three independent experiments on three healthy controls is shown. (C). T cells of HCs (n = 6) and SLE patients
(n= 10) were activated for 36 h as indicated andMMP-9 secretion analyzed by ELISA. (D) T cells of HCs (n= 8) and SLE patients (n= 10) were activated
as indicated for 36 h and sCD46 release measured. (E) T cells of HCs (n = 10) and SLE patients (n = 10) were activated as indicated for 36 h with or
without the addition of the MMP-9 inhibitor and IL-10 and IFN-y secretion measured. (F) MMP-9 inhibition restores normal Notch1 activity in
T cells from SLE patients. Quantitative RT-PCR analysis of HES1 gene transcription in resting or CD3+CD46-activated T cells (36 h)
from HCs and SLE patients with or without addition of MMP-9 inhibitor. mRNA levels were normalized to S18 ribosomal mRNA and
depicted relative to non-activated cells. Data are derived from two independent experiments with conditions performed in triplicate using
T cells from four HCs and five SLE patients. p values in (D) and (E) were calculated using the paired t test, *p < 0.05; **p < 0.005.
subsequent IL-10 switching) while MMP-9 inhibition in SLE T cells
reduces the abnormally high generation of sCD46 to levels now
allowing for normal IL-10 switching. CD46-driven IL-10 induction
in T cells is accompanied by Notch-induced induction of HES1 and
increased levels of sCD46 in T-cell cultures of HC interferes with
HES1 induction [10]. In line with this observation, restoration of
IL-10 secretion in SLE T cells with MMP-9 inhibition is indeed
accompanied by a significant increase in HES1 mRNA transcrip-
tion (Fig. 5F), an effect not present in HC T cells. Thus, these
data are in line with our published studies demonstrating that
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
8 Ursula Ellinghaus et al. Eur. J. Immunol. 2017. 0: 1–11
coordinated CD46 surface processing during and after Th1 induc-
tion is needed for normal Th1 induction and contraction [10] and
support the conclusion that MMP-9 is a physiological proteinase
in such CD46 processing on CD4+ T cells.
Discussion
Many abnormalities in B- and T-cell compartments have been
reported in SLE and these include, uncontrolled antibody pro-
duction against self-antigens, hyperactive secretion of pro-
inflammatory cytokines by effector T cells and possibly defects
in natural regulatory T-cell numbers and/or function (Tregs) [1].
We here report for the first time a defect in the CD46-mediated
IL-10 co-expression and hence normal contraction of Th1 cells in
the CD4+ T-cell pool of patients with SLE. Mechanistically, this
is driven by pathologically increased cleavage of CD46 from the
T-cell surface through the matrix metalloprotease MMP-9 lead-
ing to subsequent dysregulation of Notch-mediated signals that
prevent normal Th1 shut down (Supporting Information Fig. 1).
This finding aligns well with the recent understanding that
signals mediated by the Notch system [28] and by activation of
fragments from intracellularly processed complement components
C3 and C5 in human CD4+ T cells are critical to normal Th1
induction and contraction [29–31]. Particularly the TCR-induced
autocrine engagement of the C3aR and of CD46 (via C3a and C3b,
respectively) is a prerequisite for normal IFN-γ secretion and Th1
induction in human CD4+ T cells. Furthermore, an as yet unde-
fined signaling crosstalk between CD46 and the IL-2R (after suc-
cessful Th1 induction) contributes to IL-10 co-expression in Th1
cells and their transition into a suppressive and (self)regulating
contraction phase [9]. Similarly, coordinated Notch signaling via
engagement with Notch ligands such as Jagged1 and 2 and/or
Delta1-4 is required for normal Th1 biology [19, 32] – hence,
dysregulations in Notch and/or CD46-mediated T-cell signals con-
tribute to autoimmune diseases such as RA and MS [9, 16].
Although it is now also increasingly appreciated that that the
exact temporal and spatial control of such complexNotch and com-
plement receptor/regulator crosstalk is key to normal Th1 induc-
tion and contraction, our understanding of how this is achieved is
still limited. Both CD46 and Notch are cleaved via ADAMs from the
cell surface upon their engagement by their respective ligands and
elevated levels of sCD46 in sera of patients with active SLE, RA,
Sjogen’s syndrome, and MS have been observed [20, 21]. Uncon-
trolled activation of the complement system has previously been
linked with SLE leading to hypocomplementemia and complement
deposition at sites of tissue injury [33], however, these effects
were traditionally thought to be dependent on liver-derived and
serum-active complement. Although one study connected muta-
tions in CD46 with increased risk for onset of lupus nephritis [34]
no work has so far been performed on the role for the sCD46 shed
by (immune) cells in autoimmune disease.
Cell surface expression of CD46 is normally tightly regulated
by MMPs and their closely related family of ADAMs [18, 26].
While the biological significance of CD46 shedding remains unre-
solved for most cells, we recently demonstrated that soluble
CD46 (sCD46) modulates Notch1-mediated signals on T cells and
impacts significantly on IFN-γ to IL-10 switching and Th1 con-
traction [10]. Thus, our novel observation here that increased
MMP-9-mediated CD46 shedding by CD4+ T cells from patients
with SLE contributes to their defective IL-10 switching and Th1
contraction may deliver for the first time a mechanistic explana-
tion for the correlation between increased sCD46 and autoimmune
disease. Hypomethylation of the MMP9 promoter [35] and unre-
strained MMP-9 protein activity has indeed been reported in SLE
and further supports our notion that this protease is important in
Th1 biology via regulation of CD46 surface levels [27, 36].
The underlying reason for the increased MMP-9 expression in
T cells from patients with SLE – and whether this activity is a
direct cause or a consequence of perturbed upstream signals – is
currently unclear. Although IL-17 can induce increased MMP-9
expression in cells [37], we did not observe an increase in IL-
17 production by T cells from SLE patients under any activation
conditions tested (Supporting Information Fig. 2). TCR activa-
tion in conjunction with CD46 co-stimulation increases MMP-9
expression [11] and we observed significantly increased gener-
ation of the CD46 ligand C3b in the patients’ T cells (Fig. 1E).
Since autocrine CD46 activation also increases T-cell intrinsic C3
expression via a positive feedback loop [11], one possibility is that
dysregulated autocrine CD46 signaling – via increased intrinsic C3
activation – itself contributes to increased MMP-9 expression. This
notion aligns with our finding that CD46-driven IL-2R assembly
(Supporting Information Fig. 1) and Notch up-regulation (data
not shown) are perturbed in the patients’ T cells. Notably, failure
of Notch up-regulation in activated T cells from SLE patients has
been connected with an increase in disease activity [38]. Interest-
ingly, the CD46-triggered nuclear translocation of IL2 transcrip-
tional regulators ICER and CREM (necessary for the switch of Th1
cells into an IL-10-producing regulatory phenotype) [9] remains
unaffected (data not shown) suggesting that only certain aspects
of CD46 signals are altered in SLE T cells.
In line with our previous studies demonstrating that reduced
IL-10-switching in T cells from patients with RA correlates with
the lack of suppressive capacity, T cells from SLE patients also fail
to control bystander T-cell activation in an IL-10-dependent man-
ner (Fig. 3A). This observation may partly explain the hyperactive
Th1 response in SLE [39]. Furthermore, we have previously shown
that IL-10 co-producing Th1 cells are ‘prime’ activators of B cells
and strongly support class switching in an IL-10-dependent fash-
ion [23]. T-cell supernatants from SLE patients mediated reduced
plasmablast induction and class switching and this ‘defect’ could
be fully rescued by addition of rhIL-10 to cultures (Fig. 3C and
D). This finding suggests that the increased amounts of sCD46
present in the T-cell supernatants of SLE patients had no impact
on the B-cell activation parameters measured in our system and
could indicate that the ‘action’ of sCD46 is confined or targeted to
specific cell populations.
Although we have shown here that increased sCD46 affect nor-
mal Notch-activity and that these signals can be ‘normalized’ via
MMP-9 inhibition, the elevated sCD46 generated by SLE T cells
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will likely have additional effects that we have not yet accounted
for. For example, sCD46 binds C3b and may therefore compete
with other C3b/iC3b-fragment binding receptors for this ligand
and modulate their contributions to immune cell effector func-
tions (Supporting Information Fig. 2); particularly in vivo where
T cells operate in the context of other immune cells and tissues
and not in isolation as assessed in the in vitro system applied
here. The idea that much more work is required to understand the
complex in vivo role of autocrine complement in health and dis-
ease is underpinned by the finding that, unexpectedly, increased
numbers of IL-10-producing (and not IFN-γ producing) T cells
after CD3+CD46 activation correlate with the highest SLEDAI
score in SLE patients (Fig. 2B). The explanation for this obser-
vation is not clear but could reflect an increased number of acti-
vated and/or memory-like T-cell generation in the SLE patients
(as previously observed, [40]) as we and others have shown
that repeated T-cell stimulation correlates with accelerated IL-10
switching and memory induction [9, 41]. In this regard, although
CD46 is now firmly recognized as a key modulator of human Th1
biology, fully dissecting its diverse in vivo functions on a range
of cell populations remains a challenge as mice do not express
CD46 on somatic cells and tissues and a homologue that fully
recapitulates CD46’s functions has so far not been identified in
mice [29].
In summary, we demonstrate here that MMP-9-mediated shed-
ding of CD46 is an integral part of autocrine Th1 regulation and
that this pathway is dysregulated in T cells from patients with SLE.
Thus, targeting MMP-9 activity could potentially be a promising
candidate in the fight against SLE and possibly other autoimmune
diseases.
Methods
Healthy donors and patients
A total of 45 patients with SLE fulfilling the revised American
College of Rheumatology classification criteria were recruited
from the Hammersmith and St. Thomas‘ Hospital, London. Dis-
ease severity was assessed using the SLE disease activity index
(SLEDAI). The mean age of patients was 37 years, (M:F = 0.21).
Thirty-eight healthy volunteers had a mean age 34 years, (M:F
= 0.35). All the patients were treated with hydroxychloroquine,
some were also on low dose prednisolone and/or mycophenolate.
No patients were on high dose corticosteroids or had ever received
anti-CD20 therapy. Informed consent was obtained and ethically
approved: REC 12/LO/1273 and 07/H0718/49.
Antibodies, recombinant proteins, and inhibitors
Cell stimulating antibodies to CD3 (clone OKT-3), CD28 (clone
AF-342-PB) and CD46 (clone 344519) were all purchased from
R&D Systems. Neutralizing antibodies to IL-4 (clone 8D4-8) and
IL-10 (clone JES3-19F1) were both from BD Pharmingen. Antibod-
ies used in flow cytometric analysis were FITC-labeled anti-CD46
(clone MEM-258), BV421-labeled anti-CD122 (clone TU27), PE-
labeled anti-CD132 (clone AG184) from BioLegend, and FITC-
labeled anti-CD19 (clone 4G7-2E3) and APC-labeled anti-CD138
(clone 359103), both from R&D Systems, while the APC-labelled
anti-CD25 (clone M-A251) was purchased from BD Pharmingen.
Recombinant human IL-2 and IL-10 were purchased from Pepro-
Tech and soluble CD46 was prepared as previously described.10
The MMP-9 inhibitor was purchased from Calbiochem (CAS
1177749-58-4) and used at the concentrations indicated in the
respective experiments.
PBMC, T-cell and B-cell isolation
Peripheral mononuclear cells (PBMCs) were isolated from antico-
agulated venous blood using Ficoll density centrifugation (Sigma-
Aldrich Histopaque-1077). CD4+ T cells were isolated utilizing
CD4+ MicroBeads (Miltenyi Biotec), their purity was >97% in all
experiments. CD19+ B cells were isolated using Dynabeads (Invit-
rogen), their purity was >95% in all experiments.
B cell and T cell in vitro activation
Purified CD19+ lymphocytes (1 × 105 cells/well) were cultured
in 96-well plates in 50 μL medium (RPMI, 5%FBS) supplemented
with 50 ng/mL rhIL-10 (Miltenyi Biotec), 20 U rhIL-2 (PeproTech),
0.1 μg/mL CD40L (Enzo Life Science) and 25 μg/mL anti-human
IgM F(ab’)2 (Jackson ImmunoResearch). Purified CD4+ lympho-
cytes (2.5 × 105-3.5 × 105 cells/well) were cultured for 36 h
with rhIL-2 (PeproTech, 50U/mL) at 37°C, 5% CO2 in 48-well
plates that had been coated overnight with anti-CD3 (2 μg/mL)
(BioLegend, clone OKT3) +/-anti-CD46 (2 μg/mL) (R&D Sys-
tems, clone 344519). To assess B-cell activation, 100 μL of T-cell
supernatant was added to B cells and cultured for 5–10 days at
37°C, 5%CO2. To block the activity of IL-10, a neutralizing mAb
to IL-10 (2.5 μg/mL) was used. To restore B-cell proliferation in
mixtures containing T-cell supernatants rhIL-10 (1 μg/mL) was
added.
Suppression and proliferation assays
Purified CD4+ T cells (3 × 105) were stimulated for 36 h on
48-well plates with immobilized anti-CD3, anti-CD46, and rhIL-
2 (50 U/mL). Supernatants from these cells were harvested and
transferred to freshly isolated CD4+ T cells. T cells cultured in
medium served as a control. T cells/supernatant mixtures were
activated for 6 days with anti-CD3 ±anti-CD28. To block the activ-
ity of IL-10 in culture a neutralizing mAb to IL-10 was used at
a concentration of 2.5 μg/mL. Cell proliferation was measured
using the CellTiter96 AQueous One solution Cell Proliferation kit
(Promega).
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Cytokine measurements
Cytokines were measured using the human IFN-γ or IL-10
Cytokine Secretion Assay (Miltenyi Biotec) in combination or the
TH1/TH2 Cytometric Bead Array (BD Bioscience). Samples were
analyzed by Flow cytometry on a BD FACS Canto machine and
data analyzed using FlowJo software (V10.0.6).
Measurements of soluble CD46, MMP-9, C3b, and Ig in
cell supernatants by ELISA
Amounts of sCD46 in culture supernatants was measured by sand-
wich ELISA (detection range: 7.8–500 ng/mL): anti-CD46 (clone
GB-24),38 and biotin anti-CD46 (clone MEM-258, Novus Biologi-
cals). IgM and IgG in B cell tissue culture supernatants were ana-
lyzed using the human IgM (detection range: 15.6–1000 ng/mL)
and IgG (detection range 7.8–1000 ng/mL) ELISA quantifica-
tion (Bethyl Laboratories). MMP-9 in T cell tissue culture super-
natants was measured using the LegendMaxTM ELISA (BioLegend;
detection range: 62.5–4000 pg/mL). C3b was analyzed using the
Complement C3b human ELISA (Abcam; detection range: 0.15–
10 ng/mL).
RT-PCR for CD46 isoforms and quantitative RT-PCR
for HES1 mRNA
Total RNA was extracted from CD4+ T cells using the RNeasy
mini kit (Qiagen). To analyze the expression pattern of CD46
isoforms the following CD46-specific primers were used:5’GTGG
TCAAATGTCGATTTCCAGTAGTCG-3’ (forward) 5’CAAGCCACAT
TGCAATATTAGCTAAGCCACA-3’ (reverse). A total of 10 ng of
total RNA was used and RT-PCR was performed with the
One-Step RT-PCR (Qiagen). PCR products were analyzed using
the GelAnalyzer2010 (Agilent Technologies). For HES1 expres-
sion the following primers were used: 5′-GAAGCACCTCCGGAA
CCT-3′ (forward) 5′-GTCACCTCGTTCATGCACTC-3′ (reverse).
Statistical analyses
Statistical analysis was performed using, where appropriate, either
the two-tailed Mann–Whitney U-test, the Student’s paired t-test or
the Pearson correlation coefficient.
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